Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Graciela M. Nogueras‐González et al.|Cancer Discovery|2018Cited by 570
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Naval Daver, Sreyashi Basu et al.|Cancer|2018Cited by 339
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary CarcinomaPavlos Msaouel, Nizar M. Tannir, Gabriel G. Malouf et al.|Cancer Cell|2020Cited by 142
PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent GrowthJorge Blando, Cheryl L. Walker|American Journal Of Pathology|2009Cited by 44
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancersKwang‐Yu Chang, Li-Tzong Chen, Nai‐Jung Chiang et al.|OncoImmunology|2021Cited by 44